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SCFFbx4 was recently identified as the E3 ligase for cyclin D1. We now describe cell-cycle-dependent phos-
phorylation and dimerization of Fbx4 that is regulated by GSK3b and is defective in human cancer. We pres-
ent data demonstrating that a pathway involving Ras-Akt-GSK3b controls the temporal phosphorylation and
dimerization of the SCFFbx4 E3 ligase. Inhibition of Fbx4 activity results in accumulation of nuclear cyclin D1
and oncogenic transformation. The importance of this regulatory pathway for normal cell growth is empha-
sized by the prevalence of mutations in Fbx4 in human cancer that impair dimerization. Collectively, these
data reveal that inactivation of the cyclin D1 E3 ligase likely contributes to cyclin D1 overexpression in a
significant fraction of human cancer.INTRODUCTION
Cell-cycle progression requires the orderly accumulation of pro-
teins that drive cell division with the coordinated inactivation or
loss of proteins that inhibit this activity. Progression through
G1 phase ensues upon activation of CDK4, CDK6, and CDK2
through association with their regulatory subunits, cyclin D (D1,
D2, or D3, depending upon the tissue type) and cyclin E. Accu-
mulation of cyclins is determined largely through coordinated cy-
cles of synthesis and destruction (Sherr et al., 1992; Winston and
Pledger, 1993; Geng et al., 1996). Efforts to define the proteolytic
machinery led to the identification of SCF (Skp1-Cul1-F box pro-
tein) E3 ligases as the primary regulators of G1 cyclin proteolysis.
The F box component of SCF ligases determines substrate
specificity and generally binds to substrates in a phosphoryla-
tion-dependent manner (Skowyra et al., 1997; Willems et al.,
1999; Craig and Tyers, 1999). More specifically, cyclin D1 prote-68 Cancer Cell 14, 68–78, July 2008 ª2008 Elsevier Inc.olysis is directed by the SCFFbx4/aB-crystallin ligase, whereas cyclin
E ubiquitination is directed by SCFFbw7 ligase (Lin et al., 2006;
Koepp et al., 2001; Strohmaier et al., 2001; Welcker et al.,
2003). Accumulation of cyclin D1 is acutely sensitive to
growth-factor stimulation. Cyclin D1 initially accumulates in G1
phase through growth-factor-dependent transcription and
translation (Sherr et al., 1992). At the G1/S boundary, cyclin D1
is phosphorylated by GSK3b at the residue Thr286 followed by
CRM1-dependent nuclear export to the cytoplasm, where cyclin
D1 is recognized by SCFFbx4/aB-crystallin ligase, ubiquitinated, and
targeted to the 26S proteasome (Diehl et al., 1997; Alt et al.,
2000; Lin et al., 2006).
Cyclin D1 is overexpressed frequently in different human can-
cers such as those originating from the esophagus, head and
neck, and breast, and overexpression is considered an early,
causative event in some of these cancers (Diehl, 2002). Over-
expression was initially thought to result from chromosomalSIGNIFICANCE
Cyclin D1 overexpression occurs frequently in human cancer; however, the contributingmechanisms remain ambiguous, as
the frequency of gene amplification is lower than the incidence of overexpression. Herein we demonstrate that attenuation
of cyclin D1 SCFFbx4 E3 ubiquitin ligase activity occurs frequently in human cancer and may represent a common mecha-
nism of overexpression and deregulation of cyclin D1. Significantly, inactivation of the Fbx4 ligase is the result of mutations
in N-terminal regulatory regions of Fbx4 that disrupt ligase dimerization, thereby revealing the biological significance of SCF
ligase oligomerization. In summary, our study establishes Fbx4 as a tumor suppressor in human cancer, function of which is
abrogated by a unique category of mutations that target E3 ligase activity.
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berg et al., 1995; Nakagawa et al., 1995). Because the frequency
of cyclin D1 overexpression exceeds the frequency of such large
chromosomal alterations, it was proposed that alterations in turn-
over of cyclin D1 protein might also contribute to aberrant cyclin
D1 levels (Russell et al., 1999; Diehl, 2002). Indeed, recent work
has revealedmutations in cyclin D1 that directly inhibit phosphor-
ylation-dependent proteolysis (Moreno-Bueno et al., 2004; Ben-
zeno et al., 2006). However, such mutations are rare and imply
the occurrence of other mechanisms. Investigations that might
reveal such mechanisms have been hindered in part by our lack
of knowledge regarding the E3 ligase that directs cyclin D1 ubiq-
uitin-mediated proteolysis.With the recent identification of Fbx4/
aB-crystallin as the specificity factor that directs cyclin D1 ubiqui-
tination (Lin et al., 2006), it is now possible to ascertain whether
components of the cyclin D1 E3 ligase, Fbx4, or aB-crystallin
are subjected to genetic alterations in human cancers and may
represent potential tumor suppressor proteins in this context.
Since SCF recognition generally depends upon substrate
phosphorylation, it has been inferred that SCF ligases are consti-
tutively active, with regulation occurring mainly at the level of
substrate phosphorylation. However, recent work has revealed
that many F box proteins can function as homodimers, thereby
providing a potential means of ligase regulation. Fbw7, an E3
ligase that ubiquitinates cyclin E, c-Myc, and Notch, has been
demonstrated to form dimers, but whether dimerization regu-
lates ligase activity or substrate recognition is controversial
(Zhang and Koepp, 2006; Welcker and Clurman, 2007; Tang
et al., 2007). b-Trcp, an E3 ligase for IkB, forms both homo-
and heterodimers between two isoforms, b-Trcp1 and b-Trcp2,
with only the homodimers forming productive ligases whereas
heterodimerization is inhibitory (Suzuki et al., 2000). The mecha-
nism by which the formation of F box protein dimers promotes
substrate ubiquitination is unclear, but possible scenarios in-
clude increased concentration of substrate in the area of high
E2 activity as well as positioning of substrate in a manner that fa-
cilitates the ubiquitination of multiple lysine residues (Tang et al.,
2007). Dimerization of F box proteins is directed through the
so-called D domain. The D domain is localized N-terminal to the
Figure 1. Dimerization of Fbx4 Occurs
through Its N Terminus
(A and B) Lysates were prepared from 293T cells
transfected with vectors encoding human wild-
type Myc-tagged Fbx4 and the indicated FLAG-
Fbx4 mutant constructs. Protein complexes were
isolated by M2 affinity chromatography and de-
tected by immunoblot with Fbx4 antibody.
(C) 293T cells were cotransfected with Fbx4
constructs along with cyclin D1, CDK4, and aB-
crystallin. Twenty-four hours posttransfection, cells
were treated with MG132 for 6 hr followed by
cyclin D1 immunoprecipitation. Cyclin D1 was
detected with 13G11 monoclonal antibody.
F box region, and critical hydrophobic
residues (leucine and isoleucine) are con-
served spatially in distinct F box proteins
such as Fbw7, b-Trcp, and Fbw2 (Zhang
and Koepp, 2006). Although the phenom-
enon of ubiquitin ligase substrate adaptor self-association is es-
tablished, the functional significance of this and whether the di-
merization is constitutive or regulated remain to be elucidated.
This work provides evidence that Fbx4 contains an N-terminal
dimerization domain (D domain) and that dimerization is regu-
lated by phosphorylation of a conserved serine residue (Ser11
in mouse; Ser12 in human) proximal to the D domain. We dem-
onstrate that dimerization-deficient Fbx4 mutants fail to support
efficient cyclin D1 degradation. Mutation of this serine residue to
alanine attenuates dimerization of Fbx4 and significantly impairs
cyclin D1 ubiquitination and proteolysis. Importantly, the data re-
veal that phosphorylation of Ser11 is temporally regulated during
cell-cycle progression, with maximal phosphorylation and di-
merization occurring during S phase. Strikingly, Fbx4 phosphor-
ylation is GSK3b dependent, thereby revealing that GSK3b con-
trols not only substrate availability, through phosphorylation of
cyclin D1, but also activation of the E3 ligase that promotes cy-
clin D1 ubiquitination. Finally, we demonstrate that inhibition of
SCFFbx4/aB-crystallin ligase activity leads to accumulation of cyclin
D1 in the nuclei and promotes cellular transformation.
RESULTS
Fbx4 Contains an N-Terminal Dimerization Domain
To test Fbx4 dimerization, a series of Fbx4 deletion alleles with
an N-terminal FLAG tag (see Figure S1A available online) were
coexpressed with Myc-tagged wild-type Fbx4 in 293T cells,
and interactions were assessed by anti-FLAG precipitation.
Myc-Fbx4 was detected in precipitates containing wild-type
FLAG-Fbx4 (Figure 1A), revealing homotypic dimerization. While
neither the F box nor the C-terminal regions were required, re-
moval of the N-terminal 50 amino acids of Fbx4 abrogated di-
merization (Figure 1A, DN Fbx4). Critically, DN Fbx4 still bound
Skp1 (Figure 2A), suggesting that this deletion did not result in
global folding defects. Mutation of leucine/isoleucine residues
within Fbx4 (Figure S1B) that are spatially conserved with leu-
cines that contribute to dimerization of Fbw7 (Zhang and Koepp,
2006) defined Leu23 as essential for Fbx4 dimerization
(Figure 1B). As with dimerization-defective Fbw7 (Zhang andCancer Cell 14, 68–78, July 2008 ª2008 Elsevier Inc. 69
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D1 Ubiquitination and Proteolysis
(A) 293T cells were transfected with plasmids en-
coding FLAG-tagged Fbx4 mutants and wild-
type Myc-tagged Fbx4. Complexes were isolated
by affinity chromatography using M2-conjugated
agarose, and individual components were de-
tected by immunoblotting with Fbx4 and Skp1
antibodies.
(B) NIH 3T3 cells in which Fbx4 had previously
been knocked down by shRNA were transfected
with wild-type, S12A, or S12E Fbx4 pcDNA3 fol-
lowed by G418 selection of stably expressing
clones. Asynchronous cells were harvested and
subjected to western blotting with cyclin D1,
TRF1, and Fbx4 antibodies.
(C) Quantification of data in (B). Error bars repre-
sent ±SD.
(D) Ligase complexes (purified protein shown in
bottom panel) were purified from stable cell lines
expressing SCFFbx4, SCFS12E, or SCFS12A Fbx4
(described in [B]). In vitro ubiquitination reactions
were performed using GST-tagged purified cyclin
D1. Ubiquitin-conjugated cyclin D1 was detected
by immunoblotting. Nonspecific complexes are
denoted by asterisks.
(E) NIH 3T3 cells were serum starved for 48 hr and
released into 10% FBS-containing medium for the
indicated intervals. Immunoblot analysis was per-
formed using pSer11/12 Fbx4 and a total Fbx4
antibody.
(F) Cells synchronized via nocodazole block were
harvested at the indicated intervals following no-
codazole release. Fbx4 phosphorylation was de-
tected by precipitation with pSer11/12 antibody
and immunoblotting with total Fbx4 antibody.
Total cyclin D1 and Fbx4 levels were assessed
by direct western blotting.Koepp, 2006; Welcker and Clurman, 2007), Fbx4 mutants re-
tained their capacity to associate with cyclin D1 (Figure 1C)
and aB-crystallin (Figure S1C) (Lin et al., 2006).
Ser12 of Fbx4 Contributes to Fbx4 Dimerization
Ser12 of Fbx4 is a predicted proline-directed phosphorylation
motif (Beausoleil et al., 2004). Due to the proximity of Ser12
with the D domain, we considered the possibility that phosphor-
ylation of Ser12 could regulate dimerization of Fbx4. We there-
fore generated both nonphosphorylatable (S12A) and phospho-
mimetic (S12E) mutations in Fbx4 as well as a P13A mutant to
address whether a proline-directed kinase targeted this site;
all mutants were then assessed for dimerization potential. Both
S12A Fbx4 and P13A Fbx4 exhibited reduced dimerization po-
tential when compared to wild-type Fbx4 or S12E Fbx4
(Figure 2A). We next reconstituted murine NIH 3T3 cell lines
wherein endogenous Fbx4 had been stably knocked down (Lin
et al., 2006), using either wild-type (human) Fbx4 or the Ser12
mutants of Fbx4 followed by G418 selection to establish stable
cell lines. We demonstrated previously that Fbx4 knockdown re-
sults in overexpression of endogenous cyclin D1 (Figures 2B and
2C). Reconstitution of cells with either wild-type Fbx4 or S12E
Fbx4 resulted in a reduction of cyclin D1 to levels comparable
to parental NIH 3T3, while S12A Fbx4 had reduced activity. Sig-70 Cancer Cell 14, 68–78, July 2008 ª2008 Elsevier Inc.nificantly, levels of TRF1, the only other reported Fbx4 substrate
(Lee et al., 2006), mimicked those of cyclin D1. To assess the
contribution of Ser12 to Fbx4-dependent ubiquitination activity,
we purified wild-type and mutant SCFFbx4 ligases from NIH 3T3
stable cell lines by anti-FLAG affinity purification (Figure 2D;
Fbx4 levels are shown in the lower panel). Both wild-type Fbx4
and S12E Fbx4 catalyzed in vitro ubiquitination of cyclin D1,
while activity of S12A Fbx4 was attenuated. Thus, disruption of
Ser12 leads to decreased dimerization of Fbx4 and decreased
ubiquitination of cyclin D1.
Phosphorylation of Ser12 Is Induced in the S Phase
of the Cell Cycle
SinceSer12 is important for ligase function,we considered a sce-
nario wherein phosphorylation of Ser12 regulates Fbx4 dimeriza-
tion and ultimately ligase activity. To test this notion, we first
generated phospho-Ser11/12 (Ser11 in mouse; Ser12 in human)-
reactive antibodies (Figures S2A and S2B). If phosphorylation
of Ser12 regulates Fbx4 dimerization and ubiquitination activity,
we anticipated temporal regulation of Ser12 phosphorylation.
Because cyclin D1 ubiquitination is triggered upon G1/S transi-
tion following phosphorylation-dependent nuclear export, we
predicted peak phosphorylation of Fbx4 at the G1/S boundary.
To test this premise, NIH 3T3 cells were synchronized by serum
Cancer Cell
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of Fbx4 in the S Phase of the Cell Cycle
(A) In vitro kinase assay was performed using pu-
rified GST-tagged Fbx4 and indicated kinases.
Following in vitro phosphorylation, samples were
precipitated with pSer11/12 Fbx4 antibody and
subjected to immunoblotting with Fbx4 antibody.
(B) 293T cells were transfected with wild-type
Fbx4 along with control shGFP vector, GSK3b
shRNA vector, or a plasmid encoding wild-type
(WT) GSK3b. Fbx4 was immunoprecipitated from
cellular extracts using pSer11/12 Fbx4 antibody
48 hrs posttransfection and detected by immuno-
blotting with total Fbx4 antibody.
(C) NIH 3T3 cells were transfected with empty vec-
tor or RasV12- or Myr-Akt-expressing constructs.
Cells were synchronized by serum starvation and
released into complete medium for 6 hr (G1) or
16 hr (S). Protein extracts were processed for im-
munoblotting using pSer11/12 Fbx4, total Fbx4,
total Akt, and H-Ras antibodies.
(D) NIH 3T3 cells were transfected with vector en-
coding Myc-tagged Fbx4 and were synchronized
24 hr later in G0. Cells were released into the cell
cycle for the indicated intervals (cells were treated
with kinase inhibitors for 6 hr before harvesting
samples at the 16 hr time point). Myc-Fbx4 pull-
down was performed using Myc-agarose. Myc-
Fbx4-associated endogenous Fbx4 was detected
by immunoblotting with total Fbx4 antibody.
(E) Total cell extracts from esophageal carcinoma
cell lines (TE2, TE8, and TE12) and breast carci-
noma cell lines (T47D and MDA-MB-231) were
subjected to precipitation with pSer11/12 anti-
body followed by immunoblotting with Fbx4 anti-
body. Direct western blotting was performed using
pAkt (Ser473) and total Akt antibodies.
(F) Frozen sections from MMTV-Neu breast tu-
mors were analyzed by immunohistochemistry
using pAkt (Ser473), pSer11/12 Fbx4, and
cyclin D1. Scale bar = 8 mM.
(G) NIH 3T3 cells were arrested by serum starva-
tion followed by replating in complete media. Cy-
cloheximide (CHX) was added for the indicated intervals during G1 (6 hr postrelease) and S (16 hr postrelease) phases of the cell cycle. Cyclin D1 turnover
was analyzed by western analysis using cyclin D1 antibody.
(H) NIH 3T3 shFbx4 stable cell line was transfected with either wild-type (WT) Fbx4 or Fbx4 TRPL. Cycloheximide chase was performed in asynchronous cells
48 hr after transfection. Quantification of three independent experiments is provided; error bars represent ±SD.
(I) S12A Fbx4 and S12E Fbx4 were individually reintroduced into Fbx4 knockdown cells, and cyclin D1 turnover was assessed in S phase. Quantification of three
independent experiments is provided; error bars represent ±SD.starvation; following mitogen-triggered cell-cycle reentry,
pSer12 of Fbx4 was assessed at 0, 6, 16, and 20 hr using our
phosphospecific antibody. Phosphorylation of Ser12 was low
during cell-cycle entry but increased dramatically upon S phase
entry (16 hr) and increased further during S phase (20 hr,
Figure 2E). Cells were also synchronized with nocodazole to as-
sessSer12 phosphorylation in cells traversing theG2/M–G1 tran-
sition. Ser12 phosphorylationwas high duringG2/Mand early G1
phase (Figure 2F, 0 and 6 hr), points at which cyclin D1 levels re-
main low. By contrast, Ser12 phosphorylation was reduced dra-
matically during mid/late G1 phase when cyclin D1 levels in-
crease (8 hr) andwasagain high in earlySphase (12hr, Figure 2F).
Given the proximity of Ser12 and Pro13, we reasoned that
a proline-directed kinase likely regulates phosphorylation of
this serine residue. To identify the kinase responsible for Ser12phosphorylation, we focused on proline-directed protein kinases
known to be active or activated at the G1/S phase boundary.
Strikingly, only GSK3b efficiently phosphorylated Ser12 in vitro
as determined by IP/western (Figure 3A). Phosphorylation of
Fbx4 by GSK3b was also confirmed with recombinant proteins
in an in vitro kinase assay (Figure S3A). Additionally, while
GSK3b efficiently phosphorylated Ser12, GSK3a did not exhibit
detectable activity toward this residue in Fbx4 (Figure S3B). This
result is consistent with the capacity of GSK3b, but not GSK3a,
to function as a proline-directed kinase. We evaluated the role
of CDK2 (roscovitine) and GSK3b (LiCl and SB216763) in vivo.
Both LiCl and SB216763 reduced pSer12, while roscovitine did
not (Figure S4A).
To establish the relevance of GSK3b in vivo, we used several
independent approaches. Initially, we determined whetherCancer Cell 14, 68–78, July 2008 ª2008 Elsevier Inc. 71
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Ser12 phosphorylation. Expression of kinase-dead GSK3b effi-
ciently inhibited phosphorylation in a dose-dependent manner,
and, when total Fbx4 was immunoprecipitated from cells,
kinase-dead GSK3b associated stably with Fbx4 (Figure S4B),
demonstrating a direct interaction. We then utilized a previously
validated shRNA vector (Jin et al., 2003) to knock downGSK3b in
human cells. Knockdown of GSK3b reduced pSer12 relative to
a nonspecific shGFP RNA, while overexpression of wild-type
GSK3b increased pSer12 (Figure 3B). Finally, we determined
whether the inhibition of GSK3b activity through expression of
activated Ras (RasV12) or Akt (Myr-Akt) (Rodriguez-Viciana
et al., 1994; Cross et al., 1995) would inhibit phosphorylation of
S12. Both RasV12 and Myr-Akt inhibited pSer12 (Figure 3C),
consistent with a model wherein the Ras-Akt-GSK3b cascade
regulates Ser12 phosphorylation of Fbx4.
If phosphorylation of Ser12 regulates Fbx4 dimerization, then
dimerization of Fbx4 should parallel phosphorylation and in-
crease during S phase. NIH 3T3 cells were transfected with
a plasmid encoding 63Myc-Fbx4, synchronized by serum dep-
rivation, and released into the cell cycle. Dimerization of endog-
enous Fbx4 with Myc-Fbx4 was assessed by precipitation with
anti-Myc antibodies from lysates prepared from cells harvested
in G0, G1, and S phase of the cell cycle followed by immunoblot
with antiserum directed against total Fbx4. This approach allows
the simultaneous detection of both endogenous and ectopic
Fbx4 on the same gel and thereby allows assessment of stoichi-
ometry. Stoichiometric binding of endogenous Fbx4 to Myc-
Fbx4 was detected during S phase (16 hr) and was inhibited by
incubation of cells with a small-molecule GSK3b inhibitor, dem-
onstrating that dimerization is induced during S phase and cor-
relates with Ser12 phosphorylation by GSK3b (Figure 3D). To
corroborate GSK-dependent regulation of Fbx4 dimerization,
a plasmid encoding RasV12 or the shRNA targeting GSK3b
was introduced into 293T cells along with constructs encoding
Myc-Fbx4 and FLAG-Fbx4. Dimerization was analyzed by
FLAG pull-down and western blotting with antisera directed
against Fbx4 allowing detection of both tagged forms on a single
western blot. Inhibition of GSK3b activity through overexpres-
sion of RasV12 or GSK3b knockdown resulted in an inhibition
of Ser12 phosphorylation and decreased Fbx4 dimerization
(Figure S4C). To determine whether Fbx4 Ser12 phosphorylation
is regulated in an Akt-dependent manner in vivo, we utilized
a panel of esophageal and breast cancer cells with differential
Akt activity levels. In cells with high Akt activity (Figure 3E, TE8
and T47D), there was no detectable Ser12 phosphorylation.
This finding was also supported by the absence of immunostain-
ing with pSer11/12 antibody inMMTV-Neumouse tumors, which
exhibit high Akt activity (Figure 3F, tumor 51 versus 52). Consis-
tent with increased Akt activity downregulating ligase phosphor-
ylation (and thus activity), cyclin D1 levels were also increased in
tumors with high Akt activity.
The data presented suggest that dimerization, while not es-
sential for Fbx4-dependent ubiquitination, does potentiate this
activity. If so, cyclin D1 should exhibit increased turnover during
S phase. Indeed, the half-life of cyclin D1 was shorter during S
phase (t1/2 < 15min) than in G1 (t1/2 > 40 min) (Figure 3G). Finally,
we assessed the ability of phosphorylation-deficient or phos-
phomimetic Fbx4 mutants to rescue cyclin D1 turnover in NIH72 Cancer Cell 14, 68–78, July 2008 ª2008 Elsevier Inc.3T3 cells wherein endogenous Fbx4 is knocked down.We trans-
fected the stable shFbx4 NIH 3T3 line with human cDNAs encod-
ing either wild-type Fbx4 or S12A/S12E Fbx4 (stable cell lines,
presented in Figure 2B), synchronized cells by serum starvation,
andmeasured the half-life of cyclin D1 during S phase. The cyclin
D1 half-life was extended to almost 40 min in Fbx4 knockdown
cells (Figure 3H). In cells wherein wild-type Fbx4 was reintro-
duced, cyclin D1 turnover was restored (t1/2  15 min) such
that it was comparable with parental cells (Figure 3H;
Figure S5). Strikingly, the S12A Fbx4 mutant was not able to re-
store normal kinetics of cyclin D1 turnover, whereas S12E Fbx4
was proficient in restoring the rate of cyclin D1 proteolysis
(Figure 3I). Consistent with dimerization being critical for Fbx4-
dependent cyclin D1 turnover, the dimerization-deficient Fbx4
TRPL also failed to restore cyclin D1 turnover (Figure 3H;
Figure S5). Therefore, both phosphorylation of Ser12 and dimer-
ization of Fbx4 are required for sufficient cyclin D1 turnover in
S phase cells.
Inhibition of Cyclin D1 Proteolysis Leads to Its Nuclear
Accumulation and a Transformed Phenotype
Because Fbx4 is a critical regulator of cyclin D1 accumulation
and thus CDK4 activity, we considered it likely that Fbx4 would
exhibit tumor suppressor activities. Indeed, knockdown of either
Fbx4 or aB-crystallin in mouse fibroblasts facilitated growth of
cells in soft agar, a characteristic of neoplastic transformation
(Figures 4A and 4B). In contrast, knockdown of Fbx4 in cyclin
D1 null fibroblasts failed to induce growth in soft agar
(Figure 4C), indicating that cyclin D1 is a critical target for
SCFFbx4. We also assessed the capacity of inhibition of Fbx4
to cooperate with cyclin D1 in tumor growth. For this experiment,
mammary tumors were harvested from MMTV-D1 mice (Lin
et al., 2007) and cultured in vitro. We have found that over the
course of serial cultivation, transgene expression is reduced
and the tumorigenic phenotype of the cells is lost; we therefore
reasoned that inhibition of cyclin D1 turnover might restore tu-
morigenicity. We therefore infected mammary epithelial cells
with control empty vector or a vector encoding a dominant-neg-
ative Fbx4 allele (DF Fbx4), which extends the half-life of cyclin
D1 (Figure S6A). In this system, we were unable to achieve any
significant knockdown of Fbx4 using shRNA, and we therefore
focused on DF Fbx4 as a basis for abrogating Fbx4 function.
Cells were injected in fat pads of NOD/SCID mice, and tumor
growth was assessed. While only 1 of 5 MMTV-D1 mice formed
tumors, 4 of 7 MMTV-D1/DF Fbx4 mice formed established tu-
mors (Figure 4D).
Past work has provided evidence that accumulation of cyclin
D1-dependent kinase in the nucleus during S phase disrupts
temporal control of DNA replication through stabilization of
Cdt1 that in turn induces DNA rereplication and genomic instabil-
ity (Aggarwal et al., 2007). We therefore addressed the fate of cy-
clin D1 in cells that have decreased Fbx4 or aB-crystallin activity.
Indeed, cyclin D1 accumulated in the nucleus in cells wherein en-
dogenous Fbx4 or aB-crystallin was reduced by shRNA (Figures
5A and 5B). The differences in nuclear accumulation in Fbx4 ver-
sus aB-crystallin knockdown likely reflect knockdown efficiency,
as our degree of Fbx4 knockdown was routinely 60% while
aB-crystallin was reduced to undetectable levels (Figure 5C). As
expected with the nuclear accumulation of cyclin D1, Cdt1 was
Cancer Cell
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(A) Soft agar colony formation assay was performed using pBabe-puro, shFbx4, and shaB-crystallin knockdown cell lines. Cells were plated in soft agar and
grown for 21 days. Scale bar = 250 mM.
(B) Quantification of data in (A). Error bars represent ±SD.
(C) Same experiment as in (A) using wild-type (WT) and cyclin D1/MEFs infected with control (puro) or shFbx4 retrovirus. Scale bar = 250 mM. Levels of Fbx4
and cyclin D1 proteins are provided in the bottom panel.
(D) 106 cells were transplanted into cleared mammary fat pads of 3-week-old NOD/SCID mice. Mice were monitored for palpable tumor formation biweekly.overexpressed following knockdownof either Fbx4oraB-crystal-
lin (Figure 5C). Thus, inhibition of cyclin D1 SCFFbx4 activity leads
to nuclear accumulation of cyclin D1 and cell transformation.
Fbx4 Is Mutated in Human Esophageal Carcinoma
In a majority of cancers harboring cyclin D1 overexpression de-
fects, proteolyticmachinery have been implicated as amolecular
basis. We therefore assessed primary esophageal cancers,
which are known to frequently overexpress cyclin D1 (Nakagawa
et al., 1995; Ikeguchi et al., 2001), for mutations in Fbx4 and
aB-crystallin (CryAB). The Fbx4 DNA sequence was assessed
in 116 primary esophageal carcinomas and in matched adjacent
normal tissue. We identified and verified hemizygous missense
mutations in 14% of the primary tumors (Table 1). No mutations
were identified in aB-crystallin, and cyclin D1waswild-type in tu-
mors harboring inactivating Fbx4 mutations. A majority of the
mutations in Fbx4 occur in the N-terminal regulatory domain
and interfere with Fbx4 dimerization. Mutations that impair phos-
phorylation (S12L, P13S) and indirectly influence dimerization
along with mutations that target a critical residue within the di-
merization motif (L23Q) were detected. In addition, a proline/
threonine mutation was identified at residue 76 within the F
box (P76T); P76T impairs binding to Skp1 (Figure S6B), resulting
in a dominant-negative allele. In addition to the above described
mutations, numerous S8R mutations were identified. Mutations
in this domain, like S12L, impair Fbx4-dependent regulation of
cyclin D1 degradation (Figure S6C).
Because thesemutations should reduce total SCFFbx4 activity,
we expected that there should be a corresponding increase in theaccumulation of downstream substrates. Immunohistochemical
analysis revealed overexpression of cyclin D1 and TRF1 in
Fbx4 mutant tumors, consistent with a substrate-ligase relation-
ship (Figures 6Aand6B; Table 1). Additionally,weassessedS12L
and P13S Fbx4 dimerization properties. Both mutants exhibited
reduced dimerization potential compared with wild-type Fbx4
(Figure S6D) and consequentially were unable to catalyze rapid
cyclin D1 proteolysis (Figure S6E).We also entertained the notion
that a second ligase implicated in targeting cyclin D1 for ubiquiti-
nation in cultured cells, Fbw8,might also be inactivated in esoph-
ageal caners. However, our analysis of Fbw8 expression in
normal esophageal epithelium and tumor tissue revealed that
Fbw8 is not expressed in either normal esophageal epithelium
or associated tumors (data not shown). Given the lack of detect-
able expression of Fbw8 in this tissue,weconclude that an Fbw8-
based E3 ligase is unlikely to contribute to cyclin D1 proteolysis.
Since all identified mutations in Fbx4 are hemizygous, we set
out to determine whether mutant Fbx4 alleles exhibit domi-
nant-negative activity. NIH 3T3 fibroblasts were transfected
with wild-type Fbx4 with or without Fbx4 mutants. Overexpres-
sion of wild-type Fbx4 led to the reduction of total cyclin D1 pro-
tein levels (Figure S6F, compare lanes 1 and 2), while coexpres-
sion of S8R, S12L, or P13S Fbx4 (transfected in 1:1 ratio relative
to wild-type Fbx4) attenuated Fbx4-dependent cyclin D1 loss
(Figure S6F, lanes 3–5).
We next assessed the ability of wild-type Fbx4 or the Fbx4
S8R, S12A, and L23A mutants to restore normal growth charac-
teristics of Fbx4 knockdown fibroblasts. shFbx4 NIH 3T3 cells
were transfected with the indicated constructs (Figure 6C, lowerCancer Cell 14, 68–78, July 2008 ª2008 Elsevier Inc. 73
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(A) Immunofluorescence was performed on the indicated cell lines using 13G11 cyclin D1monoclonal antibody and counterstained with DAPI. Scale bar = 25 mM.
(B) Quantification of data in (A).
(C) Protein extracts from stable NIH 3T3 cell lines expressing shFbx4 or shaB-crystallin were analyzed by western blot using cyclin D1 and Cdt1 antibodies.panel), and their capacity to proliferate in soft agar was as-
sessed. Re-expression of wild-type Fbx4 significantly reduced
the number of colonies, while ligase-defective Fbx4 mutants
did not exhibit significant activity (Figures 6C and 6D). Alto-
gether, we provide evidence that cancer-derived Fbx4mutations
that target the GSK3b phosphorylation site in Fbx4 and affect its
dimerization have reduced activity toward cyclin D1. The mech-
anism by which these mutations contribute to tumor formation
in vivo is a subject of great interest for future studies.
DISCUSSION
To date, there is little evidence that SCF ligase activity is regu-
lated. Rather, recognition of substrates by the F box component
of SCF ligases generally relies on substrate phosphorylation. Re-
cent work, however, has revealed the presence of a dimerization
domain in F box proteins (Zhang and Koepp, 2006; Welcker and
Clurman, 2007), thereby providing a platform for potential regu-
lation through F box protein (and thus SCF) dimerization. The
work described herein reveals the presence of a D domain within
Fbx4, an F box-only subtype; the conservation of this domain
suggests that dimerization is a common feature of the SCF
ligase. Strikingly, our data demonstrate that dimerization of
Fbx4 is regulated through growth-factor-dependent phosphory-
lation of Ser12 (Ser11 in the mouse). Furthermore, Ser12 phos-
phorylation and Fbx4 dimerization are required and contribute
to an increased rate of cyclin D1 proteolysis during S phase. Sur-
prisingly, phosphorylation of Fbx4, like cyclin D1 (Diehl et al.,
1998), is catalyzed by GSK3b.
As might be expected of a negative regulator of an oncogene,
cyclin D1, our data provide evidence that Fbx4 has biological
properties consistent with a tumor suppressor. First, inactivation
or a reduction in Fbx4 levels results in the cellular acquisition of
a transformed phenotype in vitro. Of equal importance, analysis
of human esophageal cancer, in which cyclin D1 overexpression
is a common event, revealed mutations in Fbx4 that directly ab-
rogate Fbx4 dimerization or inhibit binding to core SCF compo-
nents (Skp1). All mutations identified interfere with ubiquitin li-
gase activity. In aggregate, the data presented reveal a unique74 Cancer Cell 14, 68–78, July 2008 ª2008 Elsevier Inc.mechanism of growth-factor-dependent regulation of cyclin D1
and G1/S transition through phosphorylation-dependent dimer-
ization of SCFFbx4. Our data also demonstrate direct abrogation
of this pathway in human esophageal cancer and are suggestive
of such potential in other cancers that are highlighted by cyclin
D1 overexpression.
While SCF ligases are considered constitutively active, accu-
mulating evidence suggests that regulation is much more so-
phisticated than initially appreciated. Skp2 levels are determined
in part through E2F-dependent transcription (Zhang and Wang,
2006). Likewise, b-Trcp levels can be modulated by stress-acti-
vated protein kinases (Spiegelman et al., 2001). Dimerization
represents another potential regulatory apex. In fact Skp2,
Fbw7, and b-Trcp1/2 all dimerize (Zhang and Koepp, 2006; Su-
zuki et al., 2000; Welcker and Clurman, 2007; Chew et al., 2007).
Our data support a role for temporally regulated Fbx4 dimeriza-
tion in the regulation of substrate accumulation. Like Fbw7, Fbx4
contains a D domain adjacent to the F box. We have defined leu-
cine/isoleucine residues (Leu23/28, Ile27) in Fbx4 that are essen-
tial for homodimerization. The spatial organization of these resi-
dues is conserved spatially with Leu246 and Val251, which
contribute to the dimerization of Fbw7 (Tang et al., 2007). What
distinguishes Fbx4 is the role of Ser12/Pro13, which acts as
a phosphoacceptor residue for GSK3b. The generation of
a Ser12 phosphospecific antibody reveals GSK3b-dependent
phosphorylation of this residue. Strikingly, mutation of this resi-
due to a nonphosphorylatable residue attenuated homodimeri-
zation and significantly attenuated cyclin D1 ubiquitination and
destruction. Taken together, these data suggest that phosphor-
ylation contributes to regulated self-association. The signifi-
cance of this is highlighted by mutations of Ser12 and Pro13 in
human cancer.
We noted that the peak of Fbx4 phosphorylation/dimerization
occurs at the G1/S boundary, providing evidence for temporal
regulation of Fbx4 dimerization. Significantly, at the G1/S bound-
ary, cyclin D1 undergoes nuclear export, and its levels are re-
duced through phosphorylation-dependent proteolysis (Diehl
et al., 1997); half-life measurements reveal that Fbx4 dimeriza-
tion coincides with increased cyclin D1 turnover during S phase.
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cell-cycle progression are coordinated via GSK3b, which in
turn targets both substrate (cyclin D1) and E3 ligase (SCFFbx4).
Accumulating data suggest that oncogenic functions of cyclin
D1 depend upon its nuclear accumulation during S phase (Lin
et al., 2007; Gladden et al., 2006). The nuclear deregulation of cy-
clin D1/CDK4 activity disrupts temporal regulation of DNA
replication by directly impairing proteolysis of the replication
licensing factor Cdt1 (Aggarwal et al., 2007). If nuclear overex-
pression of cyclin D1 is in fact the oncogenic event, why does
loss of components of the D1 E3 ligase promote neoplastic
growth? Critically, impaired Fbx4 or aB-crystallin also promotes
nuclear accumulation of cyclin D1 and consequent stabilization
of Cdt1, a direct consequence of nuclear cyclin D1/CDK4.
The significance of Fbx4 activity for cell homeostasis is em-
phasized by the relative frequency of mutations that impair its
Table 1. Analysis of Fbx4 Mutations in Esophageal Tumors
Tumor # Fbx4 cyclin D1 CryAB
Cyclin D1
Protein Levels
1 ESCC L23Q WT WT NA
4 EAC P13S WT WT NA
7 ESCC S12L WT WT +++
8 ESCC L23Q WT WT +++
9 ESCC WT WT WT +
10 ESCC WT WT WT +++
11 ESCC WT WT WT ++
12 ESCC WT WT WT NA
14 ESCC WT WT WT NA
15 ESCC S8R WT WT +++
16 ESCC WT WT WT NA
17 ESCC WT WT WT NA
18 ESCC WT WT WT +
19 ESCC P76T WT WT +++
21 EAC WT WT WT NA
22 EAC L23Q WT WT NA
23 EAC P76T WT WT NA
24 EAC L23Q WT WT NA
38 ESCC S8R NA NA NA
39 ESCC G30N NA NA NA
40 ESCC exon 1 24 bp
insert
NA NA NA
41 ESCC S8R NA NA NA
42 ESCC S8R NA NA NA
43 ESCC S8R NA NA NA
44 ESCC codon 18 CA
insertion
NA NA NA
Full-length cDNAs encoding Fbx4, cyclin D1, and aB-crystallin (CryAB)
were generated by first-strand RT-PCR using oligo(dT) primers followed
by PCR using specific primers. 116 total samples were sequenced in both
directions. Cyclin D1 protein expression was analyzed by immunohisto-
chemistry. ESCC, esophageal squamous cell carcinoma; EAC, esopha-
geal adenocarcinoma; WT, wild-type. NA indicates that paraffin-embed-
ded tumor tissue was not available for immunohistochemical analysis of
cyclin D1 accumulation.biochemical activity in human cancer.We identified 16mutations
in 116 esophageal tumors screened. Importantly, the fact that
these mutations are hemizygous implies that a reduction in
Fbx4 dosage is sufficient to stabilize cyclin D1 and trigger neo-
plastic growth. Consistent with this interpretation, our knock-
downs of Fbx4 typically achieved an 60% reduction in Fbx4
levels, and this was sufficient to trigger neoplastic growth. Alter-
natively, our data reveal that coexpression of mutants with wild-
type Fbx4 can attenuate Fbx4-mediated cyclin D1 turnover. This
result is expected in the case of the P76T mutation, which dis-
rupts Skp1 binding, resulting in a dominant-negative allele simi-
lar to those generated through deletion of the F box. Given that
the other mutations disrupt oligomerization rather than Skp1-
Cul1-Rbx1 recruitment, the dominant-negative activity may re-
flect titration of these ligase components into inactive com-
plexes.
In all tumor specimens that harbored Fbx4 mutations, cyclin
D1 protein levels were elevated and accumulated in the nuclei.
This observation, together with the aforementioned transforma-
tion phenotype, strongly supports the supposition that abroga-
tion of cyclin D1 E3 ligase activity is oncogenic. It also under-
scores the importance of Fbx4 dimerization for ligase activity
since the disruption of dimerization is observed in human esoph-
ageal cancer, in contrast to Fbw7, where all identified mutations
directly impair substrate binding (O’Neil et al., 2007; Thompson
et al., 2007). One can infer from the strong selection for suchmu-
tations that complete loss of Fbx4may in fact be catastrophic for
the cell.
EXPERIMENTAL PROCEDURES
Cell Culture, Plasmids, and Transfections
All mammalian cells were maintained in DMEM containing 10% fetal bovine
serum, glutamine, and antibiotics. G0 synchronizationwas achieved by culture
in medium containing 0.1% fetal bovine serum for 24 hr. Where indicated, cells
were plated at optimal density 24 hr before transfection and were transfected
the following day using Lipofectamine Plus reagent (Invitrogen). Stable cell
lines expressing Fbx4 constructs were generated by G418 (Calbiochem) se-
lection (1 mg/ml) for 21 days and subsequently cultured in medium containing
500 mg/ml G418. Insect Sf9 cells were maintained as described previously
(Summers and Smith, 1987). Human Fbx4 Myc-tagged vector was generated
by PCR of human Fbx4 with primers designed for directional cloning into
pCS2-MT plasmid (in frame with six Myc tags at the N terminus of Fbx4).
Site-Directed Mutagenesis
FLAG-tagged Fbx4 mutants were constructed by QuikChange Site-Directed
Mutagenesis Kit (Stratagene) using pcDNA3-Fbx4 plasmid as template. PCR
reactions were performed following the manufacturer’s instructions. Clones
were sequenced in their entirety to confirm the presence of mutations.
Immunoprecipitation and Western Analysis
Cells were harvested in buffer containing 50 mM HEPES (pH 8.0), 150 mM
NaCl, 2.5mMEGTA, 1mMEDTA, 0.1%Tween 20, protease, and phosphatase
inhibitors (1 mM PMSF, 20 U/ml aprotinin, 5 mg/ml leupeptin, 1 mM DTT,
0.4 mM NaF, 10 mM b-glycerophosphate, and 100 nM okadaic acid). Protein
concentration of samples was determined by BCA assay, and Fbx4 was pre-
cipitated using either M2 agarose (Sigma-Aldrich) or cyclin D1 mouse mono-
clonal antibody D1-72-13G. Proteins were resolved by SDS-PAGE, transferred
to nitrocellulose membranes, and analyzed by immunoblotting. Antibodies
used in these studies were as follows: Fbx4 rabbit polyclonal antibody (Rock-
land Immunochemicals), aB-crystallin (SPA 223) rabbit polyclonal antibody
(Stressgen), H-Ras (Santa Cruz), pSer473 Akt and Akt (Cell Signaling), cyclin
D1 mouse monoclonal antibody D1-72-13G, cyclin D1 mouse anti-humanCancer Cell 14, 68–78, July 2008 ª2008 Elsevier Inc. 75
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(A and B) Immunohistochemical analysis of cyclin D1 or TRF1 expression in esophageal tumors: S8R Fbx4, P76T Fbx4, S12L Fbx4, wild-type (WT) Fbx4, and
normal esophagus. Scale bars = 50 mM in (A) and 25 mM in (B).
(C) shFbx4 NIH 3T3 lines were transfected with the indicated Fbx4 expression vectors (immunoblot of Fbx4 levels is presented at bottom right) and assessed for
growth in soft agar for 21 days. Scale bar = 250 mM.
(D) Quantification of data in (C). Error bars represent ±SD.(AB3, Calbiochem), b-actin (Sigma-Aldrich), TRF1 rabbit polyclonal antibody
(Abcam Inc.), mouse anti-Skp1 (BD Transduction Labs). Anti-phospho-Ser11
Fbx4 (mouse, corresponding to Ser12 in human) antibody was generated by
immunizing rabbits with peptides containing pSer11 (murine-based peptide;
YenZym Antibodies, LLC) followed by affinity purification.
Immunofluorescence
NIH 3T3-derived cell lines were plated at optimal density on glass coverslips.
Twenty-four hours after splitting, cells were permeabilized with methanol:ace-
tone (1:1), washed with PBS, and incubated in primary antibody (D1-72-13G)
for 2 hr. After washing and secondary anti-mouse FITC-conjugated antibody
application, slides were mounted using antifade DAPI reagent and analyzed
by fluorescence microscopy using a Nikon Eclipse E800 microscope.
Soft Agar Transformation Assay
Anchorage-independent growth was determined by analyzing cellular growth
in semisolid medium. Cells were seeded in Iscove’s medium containing 0.65%
noble agar/10% fetal calf serum. Cells were grown for 21 days in 8% CO2.76 Cancer Cell 14, 68–78, July 2008 ª2008 Elsevier Inc.In Vitro Kinase Assay
Purified GST-tagged Fbx4 was used as a substrate for in vitro kinase reactions
(30 min at 30C). GSK3b and MAPK p38 were purchased from Cell Signaling;
GSK3a was purchased from Abcam. Cdk2 complexes were purified from Sf9
cells infected with the indicated baculoviruses.
In Vitro Ubiquitination
NIH 3T3-derived stable cell lines expressing wild-type Fbx4 and Ser12
mutants were used to purify SCFFbx4 complexes. The SCF complexes were
immunoprecipitated from the lysates using M2 agarose and incubated with
purified GST-tagged cyclin D1 phosphorylated in vitro by recombinant
GSK3b (5U), E1, E2 (UbcH5A), ATP, and ubiquitin for the indicated times at
37C. Proteins were resolved by 10% SDS-PAGE and visualized by western
blotting with anti-cyclin D1 antibody D1-72-13G11.
Analysis of Fbx4 Mutations in Human Tumors
Fbx4, cyclin D1, and aB-crystallin PCR products from normal and tumor-
derived mRNA samples were generated using human Fbx4-, cyclin D1-, and
Cancer Cell
Mutational Inactivation of Fbx4 in Human CanceraB-crystallin-specific primers. All mutations were confirmed via bidirectional
sequencing. All esophageal cancer tissues were obtained with informed
consent and with Institutional Review Board approval from the University of
Pennsylvania, Kitano Hospital (Osaka, Japan), and Peking University. Patient
deidentifiers were used.
SUPPLEMENTAL DATA
The Supplemental Data include six figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/14/1/68/DC1/.
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